Ali-Thompson Sherlissa, Daly Gordon R, Dowling Gavin P, Kilkenny Conor, Cox Luke, McGrath Jason, AlRawashdeh Ma'en M, Naidoo Sindhuja, Power Colm, Hill Arnold D K
Department of Surgery, Royal College of Surgeons in Ireland, University of Medicine and Health Sciences (RCSI), Dublin, Ireland.
Department of Surgery, Beaumont Hospital, Dublin, Ireland.
Front Oncol. 2024 May 1;14:1355353. doi: 10.3389/fonc.2024.1355353. eCollection 2024.
The overamplification of human epidermal growth factor (HER2) in breast cancer (BC) has been the subject of numerous research publications since its discovery in 1987. This is the first bibliometric analysis (BA) conducted on HER2-positive (HER2+) BC. The purpose of this BA is to analyze the published research on HER2+ BC from 1987 to 2024, highlighting the most significant scientific literature, as well as the main contributing authors and journals, and evaluating the impact of clinical and lab-based publications on HER2+ BC research.
The Web of Science Core Collection (WoSCC) was searched using the terms "Breast cancer" OR "Breast carcinoma" OR "Breast tumor" AND "HER2 positive" OR "HER2+". The search was limited by publication year (1987-2024) and only full English articles were included. WoS returned 7,469 relevant results, and from this dataset, a bibliometric analysis was conducted using the "analyze results" and "journal citation report" functions in WoS and the VOSviewer 1.6.16 software to generate bibliographic coupling and co-citation analysis of authors.
The analysis encompassed a total of 7,469 publications, revealing a notable increase in the annual number of publications, particularly in recent years. The United States, China, Italy, Germany, and Spain were the top five most prolific countries. The top five significant institutions that published HER2+ research were the University of Texas System, Unicancer, UTMD Anderson Cancer Center, Harvard University, and University of California System. , , and were the top three notable journals with the highest number of HER2+ BC publications. Dennis Slamon (Nc = 45,411, H-index = 51) and Jose Baselga (Nc = 32,592, H-index = 55) were the most prolific authors. Evolving research topics include anti-HER2 therapy in the neoadjuvant setting, treatment of metastatic HER2+ BC, and overcoming therapy resistance.
This study provides an overview of HER2+ BC research published over the past three decades. It provides insight into the most cited papers and authors, and the core journals, and identifies new trends. These manuscripts have had the highest impact in the field and reflect the continued evolution of HER2 as a therapeutic target in BC.
自1987年发现人类表皮生长因子（HER2）在乳腺癌（BC）中过度扩增以来，它一直是众多研究出版物的主题。这是首次对HER2阳性（HER2+）乳腺癌进行的文献计量分析（BA）。本次文献计量分析的目的是分析1987年至2024年发表的关于HER2+乳腺癌的研究，突出最重要的科学文献以及主要贡献作者和期刊，并评估临床和基于实验室的出版物对HER2+乳腺癌研究的影响。
在Web of Science核心合集（WoSCC）中使用检索词“乳腺癌”或“乳腺癌”或“乳腺肿瘤”以及“HER2阳性”或“HER2+”进行检索。检索受出版年份（1987 - 2024）限制，仅纳入全英文文章。WoS返回7469条相关结果，基于此数据集，使用WoS中的“分析结果”和“期刊引用报告”功能以及VOSviewer 1.6.16软件进行文献计量分析，以生成作者的文献耦合和共被引分析。
该分析共涵盖7469篇出版物，显示出年度出版物数量显著增加，尤其是近年来。美国、中国、意大利、德国和西班牙是发表量最高的五个国家。发表HER2+研究的前五大重要机构是德克萨斯大学系统、Unicancer、UTMD安德森癌症中心、哈佛大学和加利福尼亚大学系统。 、 和 是发表HER2+乳腺癌文章数量最多的前三本著名期刊。丹尼斯·斯拉蒙（Nc = 45411，H指数 = 51）和何塞·巴塞尔加（Nc = 32592，H指数 = 55）是发表量最高的作者。不断演变的研究主题包括新辅助治疗中的抗HER2疗法、转移性HER2+乳腺癌的治疗以及克服治疗耐药性。
本研究概述了过去三十年发表的HER2+乳腺癌研究。它深入了解了被引用最多的论文和作者以及核心期刊，并确定了新趋势。这些手稿在该领域产生了最高影响，反映了HER2作为乳腺癌治疗靶点的持续演变。
